Ellipses Pharma

Privately held: no public share price

Assets

(3 total)
3Total Assets
0Approved
0Phase 3 / Filed
3Phase 1–2 / Early
3Diseases
Quick filter:
Showing 3 of 3 assets
Target & Modality
Phase 1/2
RETSmall molecule
Non-Small Cell Lung Cancer
Phase 1/2
FLT3 / Aurora kinase A and BSmall molecule
Acute Myeloid Leukemia
Phase 1/2
Androgen receptor (selective)Small molecule
Breast Cancer
HR+/HER2- Metastatic Breast Cancer

Upcoming events

(4 total)

Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2026 (1)
December 2026 (1)
LunbotinibPhase 1/2Advanced Solid Tumor
Est. primary completion 2026-12-31 · NCT05265091 · CT.gov ↗
What to watch
2027 (2)
March 2027 (1)
LunbotinibPhase 1/2NSCLC
Est. primary completion 2027-03 · NCT05443126 · CT.gov ↗
What to watch
December 2027 (1)
MobinitinibPhase 1/2Acute Myeloid Leukemia, Chronic Myelomonocytic Leukemia, Myelodysplastic Syndromes
Est. primary completion 2027-12 · NCT04581512 · CT.gov ↗
What to watch
2028 (1)
February 2028 (1)
VosilasarmPhase 1/2Hormone Receptor-positive Breast Cancer, Hormone Receptor Positive HER-2 Negative Breast Cancer, Metastatic Breast Cancer
Est. primary completion 2028-02 · NCT05573126 · CT.gov ↗
What to watch

See the full readout calendar ↗

Financial reports

No financial reports recorded.